Abstract
Atenolol is a beta-adrenoreceptor blocker with relative selectivity for beta-1 receptors. It is devoid of local anesthetic activity and intrinsic sympathomimetic activity, and its lipid solubility is very low. Like other beta-adrenoreceptor blockers, atenolol is effective in treatment of angina pectoris, systemic hypertension, and cardiac arrhythmias. It reduces ischemic pain in patients with acute myocardial infarction. The cardioselectivity of atenolol disappears at high concentrations. Therefore, although it may be safer than nonselective beta-blockers in patients with pulmonary obstructive diseases or peripheral vascular disease, this safety is only relative.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Cruickshank JM: Beta-blockers, bradycardia and adverse effects. Acta Therapeutica 7:309, 1981.
Thompson DS, et al: Haemodynamic and metabolic effects of atenolol in patients with angina pectoris. Br Heart J 43:668, 1980
Amende I, et al: The effects of beta-blocker atenolol and nitroglycerin on left ventricular function and geometry in man. Circulation 60:836, 1979.
Jackson G, et al: Atenolol: once-daily cardioselective beta-blockade for angina pectoris. Circulation 61:555, 1980.
Harrison DC: Circulatory effects and clinical uses of beta-adrenergic blocking drugs. Ex-cerpta Medica, Amsterdam, 1972, p 142.
McDevitt DG, et al: Investigation of chronic dosing regimens of atenolol. Postgrad Med J [Suppl 3] 53:79, 1977.
Godenir JP, et al: Atenolol in unstable angina. Drugs [Suppl 2] 25:172, 1983.
Maistrello I: Hypertensive patients treated with atenolol: an overall assessment index. Drugs [Suppl 2] 25:69, 1983.
Douglas-Jones AP, Cruickshank JM: Once-daily atenolol in patients with mild or moderate hypertension. Br Med J 1:990, 1976.
Petrie JC, et al: Clinical studies with atenolol in hypertension. Postgrad Med J [Suppl 3] 53:173, 1977.
Alicandri CL, et al: Atenolol once daily in essential hypertension: a multicenter study. Drugs [Suppl 2] 25:70, 1983.
Floras JS, et al: Ambulatory blood pressure and its variability during randomized double-blind administration of atenolol, metoprolol, pindolol, and long acting propranolol in subjects with mild to moderate hypertension. Drugs [Suppl 2] 25:19, 1983.
Ibsen H, Sederberg-Olsen P: Changes in glomerular filtration rate during long-term treatment with propranolol in patients with arterial hypertension. Clin Sei 44:129, 1972.
Freis EG, et al: Hypertension. Am J Med 74:1033, 1983.
O’Callaghan WG, et al: Antihypertensive and renal haemodynamic effects of atenolol and nadolol in elderly hypertensive patients. Br J Clin Pharmacol 16:417, 1983.
Summa JD: Atenolol in the treatment of elderly hypertensive patients. Drugs [Suppl 2]: 86, 1983.
Coope JR: Multicentre trial of treatment of hypertension in the elderly in primary care. Drugs [Suppl 2] 25:87, 1983.
Bühler FR, et al: Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol 36:653, 1975.
Siamopoulos K, et al: A combination of chlorthalidone (12.5 mg) and atenolol (50 mg) in the elderly. Drugs [Suppl 2] 25:88, 1983.
Clausen T, Flatman JA: The effect of catecholamines on Na-K transport and membrane potential in rat soleus muscle. J Physiol (Lond) 270:383, 1977.
Ramsdale DR, et al: Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol. Am Heart J 103:459, 1982.
Perks WH, et al: Atenolol. Br J Clin Pharmacol 5:101, 1978.
Butland RJA, et al: Atenolol. Thorax 35:233, 1980.
Perks WH, et al: The effects of atenolol in patients with severe chronic airflow obstruction. Drugs [Suppl 2] 25:225, 1983.
McAinsh J: Clinical pharmacology of atenolol. Postgrad Med J [Suppl 3] 53:74, 1977.
Harron DWG, et al: Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, Sotalol and metoprolol. Clin Pharmacol Ther 29:295, 1981.
Shanks RG, et al: Correlation of reduction of exercise heart rate with blood levels of atenolol after oral and intravenous administration. Postgrad Med J [Suppl 3] 53:70, 1977.
Heel RC, et al: Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension. Drugs 17:425, 1979.
Fitzgerald JD: The biological and clinical effects of atenolol (“Tenormin”), a cardioselective beta antagonist. In: Pharmacological and biochemical properties of drug substances, vol 2, 1978.
Hansson L, et al: Hypotensive action of I.C.I. 66,082, a new beta-adrenergic blocking agent. Int J Clin Pharmacol 10:206, 1974.
Cruickshank JM, et al: Beta blockers and the central nervous system (CNS) [abstr]. In: 6th scientific meeting of the International Society of Hypertension, Goteborg, Sweden, 1979.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1988 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Schneeweiss, A., Schettler, G. (1988). Atenolol. In: Cardiovascular Drug Therapy in the Elderly. Developments in Cardiovascular Medicine, vol 72. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2063-0_37
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2063-0_37
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9225-8
Online ISBN: 978-1-4613-2063-0
eBook Packages: Springer Book Archive